Search results
Results from the WOW.Com Content Network
Atypical ductal hyperplasia (ADH) is the term used for a benign lesion of the breast that indicates an increased risk of breast cancer. [1]The name of the entity is descriptive of the lesion; ADH is characterized by cellular proliferation (hyperplasia) within one or two breast ducts and (histomorphologic) architectural abnormalities, i.e. the cells are arranged in an abnormal or atypical way ...
Larger size, nodal spread, and metastasis have a larger stage number and a worse prognosis. The main stages are: Stage 0 which is in situ disease or Paget's disease of the nipple. Stage 0 is a pre-cancerous or marker condition, either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
The histopathologic characteristics seen in these lesions are heterogenous. The cells of a lesion of invasive carcinoma NST may retain >70% ductal differentiation or appear completely undifferentiated. The tumor cells may be arranged in sheets, nests, cords, or singly distributed. They are pleomorphic (i.e., vary in size and shape).
Diagram showing ductal carcinoma in situ (DCIS). Date: 30 July 2014 (released by CRUK) Source: Original email from CRUK: Author: Cancer Research UK: Permission (Reusing this file) This image has been released as part of an open knowledge project by Cancer Research UK. If re-used, attribute to Cancer Research UK / Wikimedia Commons
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
The World Health Organization published the first tumour response criteria in 1981. However the specification documents were unclear which led to criteria adjustments and inconsistent conclusions. In the mid-1990s, an International Working Party was created to simplify and standardize response criteria; it then published RECIST in 2000.
It is important to correctly identify, as it can be confused with atypical ductal hyperplasia, cribriform ductal carcinoma in situ (DCIS), and adenoid cystic carcinoma. [ 1 ] Histomorphologic features
Syndrome of inappropriate antidiuretic hormone secretion (SIADH), also known as the syndrome of inappropriate antidiuresis (SIAD), [2] is characterized by a physiologically inappropriate release of antidiuretic hormone (ADH) either from the posterior pituitary gland, or an ectopic non-pituitary source, such as an ADH-secreting tumor in the lung. [1]